Eurofins acquired Transplant Genomics Inc. to expand the diagnostics market

Scientific, a global leader in bioanalytic testing, announced the successful acquisition of Transplant Genomics Inc. (TGI). TGI is a molecular diagnostic company that improves organ transplant results through non-invasive continuous monitoring guided by genomics.TGI provides innovative non-invasive testing services for asymptomatic inflammation and rejection responses after kidney transplantation. This testing service will complement the global range of transplant diagnostic products. The broad market provides an ideal platform for Eurofins to launch TGI's TruGraf blood test, which reliably excludes subclinical renal rejection in patients with kidney transplants with stable kidney function. The Centers for Medicare and Medicaid Services is understood to be supportive of the upcoming TruGraf.TruGraf is a blood testing product developed by TGI in collaboration with northwestern University's Integrated Transplant Center and the Scripps Institute. Doctors can use TruGraf with confidence after a kidney transplant for patients with stable kidney function, and their grafts do not require intravenous rejection or invasive testing. The technique is also expected to be used in subclinical and clinically repellent other transplanted organ types.Dr Gilles Martin, Chief Executive Officer of Eurofins, said: "We are delighted to welcome Transplant Genomics and its team of outstanding scientists to the Eurofins Group. This acquisition significantly strengthens our Group Laboratories and Eurofins' leadership in the transplant testing market and our ability to deploy the latest scientific advances to benefit patients. Dr Stan RoseTGI, said: "TGI is delighted to be a part of Eurofins, the global leader in bioanalytical testing. Joining the Eurofins Group will enable us to initiate TruGraf subclinical kidney rejection trials under optimal conditions, enabling us to improve organ transplant results for as many patients as possible. Dr , founder of TGI, said: "When we co-founded TGI, our primary and only goal was to ensure that our patients one day benefited from our research. Through this transaction, Eurofins will help TGI fully achieve its initial objectives. Theabout Transplant Genomics, Inc.Transplant Genomics Inc., a molecular diagnostic company dedicated to improving organ transplant results, initially focused on kidney transplant recipients. TGI, in collaboration with the organ transplant community, is commercializing a set of tests to diagnose and predict the immune status of transplant recipients. The test results will provide clinicians with information to optimize immunosuppressive treatment, enhance patient care and improve graft survival.About EurofinsEurofins Scientific is a leader in food, environmental, pharmaceutical, cosmetic product testing and agricultural science CRO services. Eurofins is also one of the world's leading professional clinical diagnostic testing start-ups. Eurofins has approximately 45,000 employees in more than 800 laboratories in 47 countries and offers more than 200,000 analytical methods. Through research and acquisition, the Eurofins Group leverages the latest technologies in biotechnology and analytical chemistry to provide customers with unique analytical solutions and the most comprehensive testing methods. (Arterial mesh)